Retrospective analysis of COVID-19 clinical and laboratory data: Constructing a multivariable model across different comorbidities

The clinical pathogenesis of COVID-19 necessitates a comprehensive and homogeneous study to understand the disease mechanisms. Identifying clinical symptoms and laboratory parameters as key predictors can guide prognosis and inform effective treatment strategies. This study analyzed comorbidities an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of infection and public health 2024-12, Vol.17 (12), p.102566, Article 102566
Hauptverfasser: Shokrollahi Barough, Mahdieh, Darzi, Mohammad, Yunesian, Masoud, Amini Panah, Danesh, Ghane, Yekta, Mottahedan, Sam, Sakinehpour, Sohrab, Kowsarirad, Tahereh, Hosseini-Farjam, Zahra, Amirzargar, Mohammad Reza, Dehghani, Samaneh, Shahriyary, Fahimeh, Kabiri, Mohammad Mahdi, Nojomi, Marzieh, Saraygord-Afshari, Neda, Mostofi, Seyedeh Ghazal, Yassin, Zeynab, Mojtabavi, Nazanin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The clinical pathogenesis of COVID-19 necessitates a comprehensive and homogeneous study to understand the disease mechanisms. Identifying clinical symptoms and laboratory parameters as key predictors can guide prognosis and inform effective treatment strategies. This study analyzed comorbidities and laboratory metrics to predict COVID-19 mortality using a homogeneous model. A retrospective cohort study was conducted on 7500 COVID-19 patients admitted to Rasoul Akram Hospital between 2022 and 2022. Clinical and laboratory data, along with comorbidity information, were collected and analyzed using advanced coding, data alignment, and regression analyses. Machine learning algorithms were employed to identify relevant features and calculate predictive probability scores. The frequency and mortality rates of COVID-19 among males (19.3 %) were higher than those among females (17 %) (p = 0.01, OR = 0.85, 95 % CI = 0.76–0.96). Cancer (p 
ISSN:1876-0341
1876-035X
1876-035X
DOI:10.1016/j.jiph.2024.102566